Optimi Health Corp. announced the successful completion of its proprietary natural psilocybin extraction process under GMP. Following intensive research and development, the Company has created a cutting-edge process to extract psilocybin from mushrooms, rather than relying on synthetic production.

The process significantly increases potency while maintaining the mushroom's botanical characteristics. This proprietary process not only reduces production costs but could open new possibilities associated with other naturally occurring compounds in psilocybin mushrooms. Optimi is currently the only publicly listed end-to-end Canadian manufacturer focused on the production of GMP-grade psychedelics including psilocybin and MDMA. The Company has filed a U.S. provisional patent application to protect its novel extraction process, reinforcing Optimi's ongoing commitment to intellectual property protection and industry leadership.

This application represents a significant milestone for Optimi and the broader psychedelics sector. Optimi GMP drug candidates are available to approved researchers and clinicians conducting clinical trials and to practitioners making requests through special patient access programs in jurisdictions that have been regulated by federal, state, and/or provincial authorities. Please be advised that the safety and effectiveness of Optimi's drug candidates are currently under review and have not yet been conclusively determined.

Moreover, note that Health Canada has not yet provided market authorization for any of investigational drug candidates.